![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Journal of Virology, March 2001, p. 2452-2457, Vol. 75, No. 5
Departments of
Microbiology1 and Pathology and
Laboratory Medicine,2 University of
Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6076, and Department of Microbiology, Philadelphia College of
Osteopathic Medicine, Philadelphia, Pennsylvania
19131-16943
Received 7 August 2000/Accepted 5 December 2000
Recombinant mouse hepatitis viruses (MHV) differing only in the
spike gene, containing A59, MHV-4, and MHV-2 spike genes in the
background of the A59 genome, were compared for their ability to
replicate in the liver and induce hepatitis in weanling C57BL/6 mice
infected with 500 PFU of each virus by intrahepatic injection. Penn98-1, expressing the MHV-2 spike gene, replicated to high titer in
the liver, similar to MHV-2, and induced severe hepatitis with
extensive hepatocellular necrosis. SA59R13, expressing the A59 spike gene, replicated to a somewhat lower titer and induced moderate to severe hepatitis with zonal necrosis, similar to MHV-A59. S4R21, expressing the MHV-4 spike gene, replicated to a
minimal extent and induced few if any pathological changes, similar to MHV-4. Thus, the extent of replication and the degree of hepatitis in
the liver induced by these recombinant viruses were determined largely
by the spike protein.
Various strains of mouse hepatitis
virus (MHV) induce different patterns of pathogenesis, including
enteritis, hepatitis, encephalitis, and demyelination in the mouse
(20, 21). We are considering three strains here, MHV-A59,
MHV-2, and MHV-4 (an isolate of MHV-JHM). The MHV-A59 strain is
dualtropic, producing moderate to severe hepatitis as well as mild to
moderate acute meningoencephalitis and chronic demyelination in C57BL/6
weanling mice (29, 30). The MHV-4 strain causes severe
acute encephalitis, chronic demyelination, and only minimal levels of
hepatitis (6, 23). The MHV-2 strain causes severe
hepatitis and meningitis but is unable to cause encephalitis (7,
20, 42). There are previous studies demonstrating a relationship
between attenuation of neurovirulence (6, 10, 13, 42) or
hepatitis (14, 28) and the presence of mutations and
variations in the spike (S) gene. The S protein, found on the virion
envelope and on the plasma membrane of infected cells, is responsible
for attachment to viral receptor and virus-cell fusion during viral
entry and for cell-to-cell fusion later during infection. S is a
180-kDa glycoprotein, which (in the case of most MHV spike proteins) is cleaved into two noncovalently associated 90-kDa subunits, the amino-terminal S1 and carboxy-terminal S2 subunits (14,
33). It is speculated that the S1 subunit forms the globular
head of the spike and the S2 subunit forms the membrane-bound stalk
(8). Recently, a receptor-binding activity has been
demonstrated using a recombinant protein containing the amino-terminal
330 residues of the S1 subunit of MHV-JHM (25, 41). S2 is
believed to contain the domain that mediates fusion of viral and cell
membranes (5, 8). The MHV-2 spike, while highly homologous
in sequence to the spike proteins of other MHV strains, remains
uncleaved and does not mediate fusion (44, 45).
Using targeted recombination technology (11, 12, 35), we
have directly demonstrated that the spike protein is a major determinant of the neuropathogenic properties of MHV (39).
When the S gene of MHV-4 was introduced into the background of MHV-A59, the resulting recombinant viruses (S4R21 and
S4R22) were highly neurotropic, displaying similar
pathogenic properties to parental MHV-4 after intracerebral inoculation
into mice. These experiments did not address the question of whether
the hepatitis phenotype of the recombinant viruses is also determined
by the spike protein.
In order to more completely explore the role of the spike protein in
controlling the ability to induce hepatitis, we compared three isogenic
recombinant viruses that differ only in the spike gene, expressing the
spike protein of A59 (SA59R13), MHV-2 (Penn98-1), or MHV-4
(S4R21) in the background of the A59 genome. This study shows that the level of viral replication in the liver is determined by
the spike gene and that the amount of antigen staining and necrosis in
the liver correlates with the level of viral replication. Thus, the
ability to induce hepatitis is largely determined by the spike gene.
We have previously described the targeted recombination technology used
to select recombinant viruses differing only in the spike gene,
including the wild-type A59 recombinants and the MHV-4 spike-containing
recombinant viruses that we have compared for neuropathogenesis
(32, 39). In this study, we are using, in addition, a
third type of recombinant virus only containing the MHV-2 spike gene,
as described by Das Sarma et al. (7). Briefly, recombinant
viruses were selected using the Alb4 mutant of MHV-A59 and synthetic
capped RNA transcribed from pMH54, a plasmid containing a portion of
the A59 HE pseudogene through the 3' end of the genome (26) with the MHV-4 or MHV-2 spike gene substituted for
the MHV-A59 spike gene (7, 39). In the experiments
described below, we used SA59R13, a wild-type recombinant
expressing the MHV-A59 spike protein; S4R21, expressing the
MHV-4 spike protein; and Penn 98-1, expressing the MHV-2 spike protein.
The spike genes of Penn98-1, S4R21, and SA59R13
were sequenced and shown to be identical to those from the parental
viruses. In every case, a second independent recombinant had the
identical spike gene sequence and displayed the same properties. Figure
1 shows a schematic diagram of these
recombinant viruses.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.5.2452-2457.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Murine Coronavirus Spike Protein Determines the
Ability of the Virus To Replicate in the Liver and Cause
Hepatitis
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
View larger version (16K):
[in a new window]
FIG. 1.
Schematic diagram of MHV-A59 genome and generated
recombinant viruses. The MHV genome is 31 kb. The sizes of the genes
are drawn approximately to scale except for gene 1. Viral genes
encoding nonstructural proteins (1a, 1b, 2a, 4a and b, and 5a) and
structural proteins (HE, spike, E, M, N, and the internal gene I) are
indicated. SA59R13, used as a control recombinant virus,
has the A59 spike reintroduced in the A59 background genome.
S4R21 and Penn98-1 recombinant viruses present the MHV-4
and the MHV-2 spike genes in the MHV-A59 background, respectively.
We initially compared the replication in the liver of the parental
MHV-A59, MHV-2, and MHV-4 (Fig. 2) by
inoculating 500 PFU of each virus directly into the liver of weanling
C57BL/6 mice (The Jackson Laboratory, Bar Harbor, Maine). We used
direct intrahepatic rather than intracerebral inoculation because this
eliminates the central nervous system (CNS) disease induced by MHV-A59
and MHV-4 and isolates the hepatitis. We have previously shown that this method delivers virus into the liver (17). Mice were
sacrificed at 1, 3, 5, and 7 days postinfection (p.i.). After perfusion
of animals with phosphate-buffered saline, livers were homogenized, and
virus was titrated on L-2 cells, as previously described
(17). While the nonhepatotropic MHV-4 replicated only
slightly above the level of detection, both A59 and MHV-2 replicated
efficiently, higher in the case of MHV-2, peaking at day 5, as
previously observed for MHV-A59 (18, 31) (Fig. 2). This is
consistent with previous results reported for these strains of virus
(20).
|
Recombinant viruses SA59R13, Penn98-1, and S4R21 were inoculated intrahepatically into weanling mice, which were sacrificed at selected times postinfection, and viruses from liver homogenates were titrated as described above (Fig. 2). All of the recombinant viruses replicated at levels similar to those of the parental strains. At day 5 p.i., Penn98-1 virus replicated to one log higher than SA59R13 and 3 logs over S4R21 (Penn98-1 versus SA59R13, P < 0.03; Penn98-1 versus S4R21, P < 0.004; Wilcoxon's rank sum test). The MHV-4 spike-containing recombinant virus (S4R21), like MHV-4 itself, replicated to a minimal extent above the level of detection (Fig. 2). Thus, since all the recombinants had the same MHV-A59 background, the level of replication was largely determined by the spike.
In order to further assess hepatitis induced by these viruses, histopathology studies on liver sections were performed. For histological diagnosis, formalin-fixed liver tissue was embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Hepatitis was scored as mild, moderate, or severe with the following criteria: (i) mild hepatitis (level 1): very few, small foci of inflammation and hepatocellular necrosis; (ii) moderate hepatitis (level 2): multiple foci of hepatocellular necrosis separated by normal liver; and (iii) severe hepatitis (level 3): either diffuse confluent (bridging) lesions or multiple foci. Replicate sections were stained immunohistochemically. All slides were read in a blinded manner. Briefly, sections were incubated with a monoclonal antibody (MAb) against the nucleocapsid protein (N) of MHV-JHM (MAb clone 1-16-1, kindly provided by J. L. Leibowitz, Texas A&M University), and immunohistochemistry was performed by the avidin-biotin-immunoperoxidase technique (Vector Laboratories, Burlingame, Calif.) using diaminobenzadine tetrahydrochloride as the substrate and counterstained with methyl green (Dako, Carpinteria, Calif.). As controls, replicate sections of each sample were incubated with an unrelated antibody (mouse immunoglobulin G, 10 µg/ml) and with secondary antibody alone. Furthermore, liver sections from mock-infected mice were incubated with the anti-N (MHV) MAb. These data are shown in Figs. 3, 4, and 5. Only the data obtained with the recombinant viruses are shown, as representative of data also observed in their parental viruses.
First, we found that the spike protein determines the degree of
hepatitis (Fig. 3A). The degree of
hepatitis induced by SA59R13 was less severe than the
extreme hepatitis induced by Penn 98-1 (P < 0.05,
Wilcoxon's rank sum test), whereas S4R21 induced mild hepatitis (SA59R13 versus S4R21, P < 0.05; Penn98-1 versus S4R21, P < 0.01; Wilcoxon's rank sum test). Second, we found a correlation between the viral replication titers and the degree of hepatitis induced by each virus (Spearman's correlation coefficient:
r = 0.85, P < 0.001, Fig. 3B). Third,
the extent of hepatocellular injury was also monitored by counting the
number of nonconfluent necrotic foci per liver section, and this
analysis also demonstrated a positive correlation between virus titers
and the severity of hepatitis (Spearman's correlation coefficient:
r = 0.88, P < 0.001) (Fig. 3C).
|
Figures 4 and 5 show immunohistochemistry staining of liver
sections from SA59R13-, Penn98-1-, and
S4R21-infected mice by day 5 p.i. At low magnification
(Fig. 4), Penn98-1 showed evidence of
extensive hepatocellular necrosis, whereas SA59R13 showed
several areas of focal necrosis. The antigen staining always
colocalized with the necrotic areas. In contrast, in
S4R21-infected livers, the hepatic parenchyma appeared
almost normal, with very low levels of antigen staining. Higher
magnification (Fig. 5) revealed
inflammatory cell infiltration associated with necrotic areas in the
livers infected by SA59R13 and Penn98-1. Livers from
animals infected with either SA59R13 or Penn98-1 also
exhibited staining of sinusoidal lining cells (consistent with Kupfer
or endothelial cells or both). In the case of Penn98-1-infected
animals, hepatocellular degeneration and necrosis were so extreme that
it was not possible to find isolated hepatocytes immunoreactive for
viral antigen, while in the livers of SA59R13-infected
animals, staining was observed both in necrotic foci and in isolated
hepatocytes. Finally, livers from animals infected with
S4R21 showed viral antigen staining in sinusoidal lining
cells and small clusters of hepatocytes as well as in isolated
hepatocytes. Little if any tissue destruction or inflammation was
observed. This is consistent with the minimal level of virus
replication observed with S4R21.
|
|
Thus, our results indicate that substitution of the spike gene of either MHV-2 or MHV-4 for the MHV-A59 spike gene within the A59 genome is sufficient to produce the hepatitis phenotype of the strain from which the spike is derived. This is not surprising, since the spike is responsible for viral attachment to the receptor, entry, and cell-to-cell fusion, and thus it may be expected to play a crucial role in initiation of infection as well as in spread of the virus. It is noteworthy that the S protein of MHV has recently been exchanged by targeted RNA recombination for the S protein of feline infectious peritonitis virus. The resulting chimeric virus acquired the ability to infect feline cells and lost the ability to infect murine cells, demonstrating that receptor utilization is a major factor in determining the host range of coronavirus infections (26).
It is likely that interaction of the spike and the viral receptor may play a role in the outcome of infection in the liver. We have previously shown that a one-amino-acid substitution, Q159L, within the amino-terminal region of the MHV-A59 spike, a region that has been demonstrated to bind to receptor in an vitro assay, results in the inability of the virus to replicate in the liver and induce hepatitis (32). This suggests that the ability to induce hepatitis may be regulated at the receptor level. Indeed, there are differences in the interaction of the MHV-A59 and MHV-4 spikes with viral receptors (46). The primary cellular receptor for MHV is a transmembrane glycoprotein of the murine biliary glycoprotein (Bgp) subfamily of the carcinoembryonic antigen family, also known as MHVR or Bgpla. Bgpla is found on epithelial and endothelial cells as well as on B lymphocytes and macrophages. Godfraind et al. (16) recently found that in the liver, Bgpla expression correlates with infection of hepatocytes and endothelial cells, leading to the development of hepatitis.
Both parenchyma cells (mostly hepatocytes) and sinusoidal lining cells (endothelial and/or Kupfer cells) express viral antigen after infection with all three viruses, and similar patterns of labeled sinusoidal lining vessel cells are found. The major difference among the strains lies in the hepatocellular degeneration and necrosis induced by each virus. Consistent with this is the staining of the hepatocytes. In liver sections from S4R21-infected mice, a few isolated labeled hepatocytes are observed. In the case of SA59R13-infected mice, there are many more labeled hepatocytes as well as antigen-positive necrotic foci. With Penn98-1, there are nearly confluent antigen-positive necrotic foci. These results suggest that endothelial and/or Kupfer cells may be infected by all three viruses but that spread into the parenchymal hepatocytes is greatly reduced with S4R21. We have previously observed that both MHV-A59 (19) and a very weakly hepatotropic strain (C12) (unpublished results) replicate to very similar low titers, suggesting that the hepatocytes are not a major site of replication for MHV-A59. By comparing the highly hepatotropic MHV-3 with MHV-4, it has been also demonstrated that replication in hepatic endothelial cells but not hepatocytes correlated with hepatotropism (22, 34, 37, 38). Our data are consistent with the notion that all three strains may infect the vessel cells but that replication and/or spread from these cells into hepatocytes might be much less efficient with MHV-4.
Belyarsky et al. (2) found that MHV-3, a strain that results in lethal fulminant hepatic necrosis in susceptible mice (9), is capable of inducing apoptosis in primary macrophage cultures. Schwartz et al. (40) have demonstrated that acute infection with MHV-A59, MHV-2, and the recombinant Penn98-1 induces apoptosis in hepatocytes and inflammatory cells. It is also known that the murine coronavirus spike contains both B-cell and T-cell epitopes (3, 4); thus, differences in spike sequences might have a major effect on the immune response. Interestingly, recent data obtained in various mouse hepatitis models for fulminant hepatitis indicate that Fas-mediated apoptosis plays an important role in the cytotoxicity induced by hepatitis virus-specific cytotoxic T lymphocytes against virus-infected hepatocytes (1, 24, 27). Taking all these data together, it may be argued that both apoptosis and the immune response play a role in MHV-induced hepatitis.
Finally, it should be noted that there is a noticeable difference in the pathogenesis of MHV in the liver and the CNS in that the extent of replication of the recombinant viruses in the CNS did not predict the amount of inflammation and disease or the virulence of the recombinant viruses. In the CNS, while S4R21 (and other MHV-4 spike-containing recombinant viruses) are approximately 1,000-fold more virulent than SA59R13 and other A59 spike-containing wild-type recombinant viruses and induce more inflammation and significantly more viral antigen, both viruses replicate to similar levels (39). In the liver, the amount of replication correlates with the extent of hepatitis. Thus, S4R21 and its parent MHV-4 replicate minimally in the liver and induce minimal hepatitis, while SA59R13 and its parent A59 replicate to a significant degree, causing an intermediate level of viral antigen expression and necrosis in the liver. Finally, Penn98-1 and its parent MHV-2 replicate to the highest levels in the liver and induce extensive hepatocellular necrosis.
Future studies will be directed at elucidating the mechanisms which control the ability of the spike to induce various levels of hepatitis. We are starting by mapping the regions of the spike protein that control hepatotropism.
| |
ACKNOWLEDGMENTS |
|---|
We thank Julian L. Leibowitz for providing MAb clone 1-16-1.
This work was supported by Public Health Service grants NS-21954 and NS30606 (S.R.W.) and National Multiple Sclerosis Society grant RG-2615A1/2 (E.L.).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, University of Pennsylvania School of Medicine, 36th Street and Hamilton Walk, Philadelphia, PA 19104-6076. Phone: (215) 898-8013. Fax: (215) 573-4858. E-mail: weisssr{at}mail.med.upenn.edu.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. |
Ando, K.,
T. Moriyama,
L. G. Guidotti,
S. Wirth,
R. D. Schreiber,
H. J. Schlicht,
S. N. Huang, and F. V. Chisari.
1993.
Mechanisms of class I restricted immunopathology: a transgenic mouse model of fulminant hepatitis.
J. Exp. Med.
178:1541-1554 |
| 2. | Belyavskyi, M., E. Belyavskaya, G. A. Levy, and J. L. Leibowitz. 1998. Coronavirus MHV-3-induced apoptosis in macrophages. Virology 250:41-49[CrossRef][Medline]. |
| 3. |
Bergmann, C. C.,
Q. Yao,
M. Lin, and S. A. Stohlman.
1996.
The JHM strain of mouse hepatitis virus induces a spike protein-specific Db-restricted cytotoxic T cell response.
J. Gen. Virol.
77:315-325 |
| 4. | Castro, R. F., and S. Perlman. 1995. CD8+ T-cell epitopes within the surface glycoprotein of a neurotropic coronavirus and correlation with pathogenicity. J. Virol. 69:8127-8131[Abstract]. |
| 5. |
Chambers, P.,
C. R. Pringle, and A. J. Easton.
1990.
Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins.
J. Gen. Virol.
71:3075-3080 |
| 6. |
Dalziel, R. G.,
P. W. Lampert,
P. J. Talbot, and M. J. Buchmeier.
1986.
Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence.
J. Virol.
59:463-471 |
| 7. |
Das Sarma, J.,
L. Fu,
J. C. Tsai,
S. R. Weiss, and E. Lavi.
2000.
Demyelination determinants map to the spike glycoprotein gene of coronavirus mouse hepatitis virus.
J. Virol.
74:9206-9213 |
| 8. | de Groot, R. J., W. Luytjes, M. C. Horzinek, B. A. van der Zeijst, W. J. Spaan, and J. A. Lenstra. 1987. Evidence for a coiled-coil structure in the spike proteins of coronaviruses. J. Mol. Biol. 196:963-966[CrossRef][Medline]. |
| 9. | Ding, J. W., Q. Ning, M. F. Liu, A. Lai, J. Leibowitz, K. M. Peltekian, E. H. Cole, L. S. Fung, C. Holloway, P. A. Marsden, H. Yeger, M. J. Phillips, and G. A. Levy. 1997. Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase. J. Virol. 71:9223-9230[Abstract]. |
| 10. | Fazakerley, J. K., S. E. Parker, F. Bloom, and M. J. Buchmeier. 1992. The V5A13.1 envelope glycoprotein deletion mutant of mouse hepatitis virus type-4 is neuroattenuated by its reduced rate of spread in the central nervous system. Virology 187:178-188[CrossRef][Medline]. |
| 11. | Fischer, F., D. Peng, S. T. Hingley, S. R. Weiss, and P. S. Masters. 1997. The internal open reading frame within the nucleocapsid gene of mouse hepatitis virus encodes a structural protein that is not essential for viral replication. J. Virol. 71:996-1003[Abstract]. |
| 12. | Fischer, F., C. F. Stegen, C. A. Koetzner, and P. S. Masters. 1997. Analysis of a recombinant mouse hepatitis virus expressing a foreign gene reveals a novel aspect of coronavirus transcription. J. Virol. 71:5148-5160[Abstract]. |
| 13. |
Fleming, J. O.,
M. D. Trousdale,
F. A. el-Zaatari,
S. A. Stohlman, and L. P. Weiner.
1986.
Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies.
J. Virol.
58:869-875 |
| 14. |
Frana, M. F.,
J. N. Behnke,
L. S. Sturman, and K. V. Holmes.
1985.
Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: host-dependent differences in proteolytic cleavage and cell fusion.
J. Virol.
56:912-920 |
| 15. |
Gallagher, T. M.,
S. E. Parker, and M. J. Buchmeier.
1990.
Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein.
J. Virol.
64:731-741 |
| 16. | Godfraind, C., and J. P. Coutelier. 1998. Morphological analysis of mouse hepatitis virus A59-induced pathology with regard to viral receptor expression. Histol. Histopathol. 13:181-199[Medline]. |
| 17. | Hingley, S. T., J. L. Gombold, E. Lavi, and S. R. Weiss. 1994. MHV-A59 fusion mutants are attenuated and display altered hepatotropism. Virology 200:1-10[CrossRef][Medline]. |
| 18. | Hingley, S. T., J. L. Gombold, E. Lavi, and S. R. Weiss. 1995. Hepatitis mutants of mouse hepatitis virus strain A59. Adv. Exp. Med. Biol. 380:577-582[Medline]. |
| 19. |
Hingley, S. T.,
I. Lepare-Goffart, and S. R. Weiss.
1998.
The spike protein of murine coronavirus mouse hepatitis virus strain A59 is not cleaved in primary glial cells and primary hepatocytes.
J. Virol.
72:1606-1609 |
| 20. | Hirano, N., T. Murakami, F. Taguchi, K. Fujiwara, and M. Matumoto. 1981. Comparison of mouse hepatitis virus strains for pathogenicity in weanling mice infected by various routes. Arch. Virol. 70:69-73[CrossRef][Medline]. |
| 21. | Houtman, J. J., and J. O. Fleming. 1996. Pathogenesis of mouse hepatitis virus-induced demyelination. J. Neurovirol. 2:361-376[Medline]. |
| 22. | Joseph, J., R. Kim, K. Siebert, F. D. Lublin, C. Offenbach, and R. L. Knobler. 1995. Organ specific endothelial cell heterogeneity influences differential replication and cytopathogenicity of MHV-3 and MHV-4: implications in viral tropism. Adv. Exp. Med. Biol. 380:43-50[Medline]. |
| 23. |
Knobler, R. L.,
M. V. Haspel, and M. B. Oldstone.
1981.
Mouse hepatitis virus type 4 (JHM strains). induced fatal central nervous system disease. I. Genetic control and murine neuron as the susceptible site of disease.
J. Exp. Med.
153:832-843 |
| 24. | Kondo, T., T. Suda, H. Fukuyama, M. Adachi, and S. Nagata. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3:409-413[CrossRef][Medline]. |
| 25. |
Kubo, H.,
Y. K. Yamada, and F. Taguchi.
1994.
Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein.
J. Virol.
68:5403-5410 |
| 26. |
Kuo, L.,
G. J. Godeke,
M. J. Raamsman,
P. S. Masters, and P. J. Rottier.
2000.
Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier.
J. Virol.
74:1393-1406 |
| 27. | Lacronique, V., A. Mignon, M. Fabre, B. Viollet, N. Rouquet, T. Molina, A. Porteu, A. Henrion, D. Bouscary, P. Varlet, V. Joulin, and A. Kahn. 1996. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 2:80-86[CrossRef][Medline]. |
| 28. | Lamontagne, L., C. Page, and J. P. Martin. 1995. T cell immunodeficiency involved in pathogenicity of attenuated MHV-3 mutants. Adv. Exp. Med. Biol. 380:189-191[Medline]. |
| 29. |
Lavi, E.,
D. H. Gilden,
Z. Wroblewska,
L. B. Rorke, and S. R. Weiss.
1984.
Experimental demyelination produced by the A59 strain of mouse hepatitis virus.
Neurology
34:597-603 |
| 30. | Lavi, E., D. H. Gilden, M. K Highkin, and S. R. Weiss. 1986. The organ tropism of mouse hepatitis virus A59 in mice is dependent on dose and route of inoculation. Lab. Anim. Sci. 36:130-135[Medline]. |
| 31. | Lepare-Goffart, I., S. T. Hingley, M. M. Chua, X. Jiang, E. Lavi, and S. R. Weiss. 1997. Altered pathogenesis of a mutant of the murine coronavirus MHV-A59 is associated with a Q159L amino acid substitution in the spike protein. Virology 239:1-10[CrossRef][Medline]. |
| 32. |
Lepare-Goffart, I.,
S. T. Hingley,
M. M. Chua,
J. J. Phillips,
E. Lavi, and S. R. Weiss.
1998.
Targeted recombination within the spike gene of murine coronavirus mouse hepatitis virus-A59: Q159 is a determinant of hepatotropism.
J. Virol.
72:9628-9636 |
| 33. | Luytjes, W., L. S. Sturman, P. J. Bredenbeek, J. Charite, B. A. van der Zeijst, M. C. Horzinek, and W. J. Spaan. 1987. Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site. Virology 161:479-487[CrossRef][Medline]. |
| 34. | Martin, J. P., W. Chen, G. Obert, and F. Koehren. 1990. Characterization of attenuated mutants of MHV-3: importance of the E2 protein in organ tropism and infection of isolated liver cells. Adv. Exp. Med. Biol. 276:403-410[Medline]. |
| 35. | Masters, P. S., C. A. Koetzner, D. Peng, M. M. Parker, C. S. Ricard, and L. S. Sturman. 1993. Site-directed mutagenesis of the genome of mouse hepatitis virus by targeted RNA recombination. Adv. Exp. Med. Biol. 342:143-148[Medline]. |
| 36. | Parker, S. E., T. M. Gallagher, and M. J. Buchmeier. 1989. Sequence analysis reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein gene of several strains of murine hepatitis virus. Virology 173:664-673[CrossRef][Medline]. |
| 37. | Pereira, C. A., A. M. Steffan, and A. Kirn. 1984. Kupffer and endothelial liver cell damage renders A/J mice susceptible to mouse hepatitis virus type 3. Virus Res. 1:557-563[CrossRef][Medline]. |
| 38. |
Pereira, C. A.,
A. M. Steffan, and A. Kirn.
1984.
Interaction between mouse hepatitis viruses and primary cultures of Kupffer and endothelial liver cells from resistant and susceptible inbred mouse strains.
J. Gen. Virol.
65:1617-1620 |
| 39. |
Phillips, J. J.,
M. M. Chua,
E. Lavi, and S. R. Weiss.
1999.
Pathogenesis of chimeric MHV4/MHV-A59 recombinant viruses: the murine coronavirus spike protein is a major determinant of neurovirulence.
J. Virol.
73:7752-7760 |
| 40. | Schwartz, T., L. Fu, and E. Lavi. Programmed cell death in MHV-induced demyelination. Adv. Exp. Med. Biol., in press. |
| 41. | Suzuki, H., and F. Taguchi. 1996. Analysis of the receptor-binding site of murine coronavirus spike protein. J. Virol. 70:2632-2636[Abstract]. |
| 42. |
Wege, H.,
J. R. Stephenson,
M. Koga,
H. Wege, and V. ter Meulen.
1981.
Genetic variation of neurotropic and non-neurotropic murine coronaviruses.
J. Gen. Virol.
54:67-74 |
| 43. |
Wege, H.,
J. Winter, and R. Meyermann.
1988.
The peplomer protein E2 of coronavirus JHM as a determinant of neurovirulence: definition of critical epitopes by variant analysis.
J. Gen. Virol.
69:87-98 |
| 44. | Yamada, Y. K., K. Takimoto, M. Yabe, and F. Taguchi. 1998. Requirement of proteolytic cleavage of the murine coronavirus MHV-2 spike protein for fusion activity. Adv. Exp. Med. Biol. 440:89-93[Medline]. |
| 45. | Yamada, Y. K., K. Takimoto, M. Yabe, and F. Taguchi. 1997. Acquired fusion activity of a murine coronavirus MHV-2 variant with mutations in the proteolytic cleavage site and the signal sequence of the S protein. Virology 227:215-219[CrossRef][Medline]. |
| 46. |
Zelus, B. D.,
D. R. Wessner,
R. K. Williams,
M. N. Pensiero,
F. T. Phibbs,
M. deSouza,
G. S. Dveksler, and K. V. Holmes.
1998.
Purified, soluble recombinant mouse hepatitis virus receptor, Bgp1(b), and Bgp2 murine coronavirus receptors differ in mouse hepatitis virus binding and neutralizing activities.
J. Virol.
72:7237-7244 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|
